Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Ford

Showing results (991-1000 of 1,097) with videos related to

Pageof 110
Sort By:
Circulation|October 5, 2011
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)Linda B Piller, Sarah Baraniuk, Lara M Simpson, et al.
American Journal of Epidemiology|July 19, 2019
Validation of the Oxford WebQ Online 24-Hour Dietary Questionnaire Using BiomarkersDarren C Greenwood, Laura J Hardie, Gary S Frost, et al.
Journal of Clinical and Translational Science|January 17, 2024
Development, implementation, and dissemination of operational innovations across the trial innovation networkMarisha E Palm, Terri L Edwards, Cortney Wieber, et al.
Oecologia|January 23, 2021
Detecting turnover among complex communities using null models: a case study with sky-island haemosporidian parasitesLisa N Barrow, Selina M Bauernfeind, Paxton A Cruz, et al.
Journal of Medicinal Chemistry|April 10, 1999
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacementsP S Dragovich, T J Prins, R Zhou, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 29, 1999
Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypesD A Matthews, P S Dragovich, S E Webber, et al.
Journal of Clinical and Translational Science|July 3, 2023
Approaches for enhancing the informativeness and quality of clinical trials: Innovations and principles for implementing multicenter trials from the Trial Innovation NetworkKaren Lane, Marisha E Palm, Eve Marion, et al.
JAMA Network Open|June 26, 2024
Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 DiabetesDaniel Edmonston, Elizabeth Lydon, Hillary Mulder, et al.
Cancers|November 27, 2025
Design and Interim Recruitment Outcomes of a Multi-Modal, Multi-Level Patient Navigation Intervention for Lung Cancer Screening in the Southeast U.SMarvella E Ford, Louise Henderson, Alison Brenner, et al.
American Journal of Preventive Cardiology|September 2, 2025
Real-world prescribing in accordance to ACC/AHA guidelines for lipid-lowering therapy in high-risk primary and secondary prevention of ASCVD: Real-World Prescribing for Lipid-Lowering TherapyJonathan Arnold, Deeksha Acharya, Hetal Boricha, et al.
Pageof 110

Showing results (991-1000 of 1,097) with videos related to

Sort By:
Pageof 110
Circulation|October 5, 2011
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)Linda B Piller, Sarah Baraniuk, Lara M Simpson, et al.
American Journal of Epidemiology|July 19, 2019
Validation of the Oxford WebQ Online 24-Hour Dietary Questionnaire Using BiomarkersDarren C Greenwood, Laura J Hardie, Gary S Frost, et al.
Journal of Clinical and Translational Science|January 17, 2024
Development, implementation, and dissemination of operational innovations across the trial innovation networkMarisha E Palm, Terri L Edwards, Cortney Wieber, et al.
Oecologia|January 23, 2021
Detecting turnover among complex communities using null models: a case study with sky-island haemosporidian parasitesLisa N Barrow, Selina M Bauernfeind, Paxton A Cruz, et al.
Journal of Medicinal Chemistry|April 10, 1999
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacementsP S Dragovich, T J Prins, R Zhou, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 29, 1999
Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypesD A Matthews, P S Dragovich, S E Webber, et al.
Journal of Clinical and Translational Science|July 3, 2023
Approaches for enhancing the informativeness and quality of clinical trials: Innovations and principles for implementing multicenter trials from the Trial Innovation NetworkKaren Lane, Marisha E Palm, Eve Marion, et al.
JAMA Network Open|June 26, 2024
Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 DiabetesDaniel Edmonston, Elizabeth Lydon, Hillary Mulder, et al.
Cancers|November 27, 2025
Design and Interim Recruitment Outcomes of a Multi-Modal, Multi-Level Patient Navigation Intervention for Lung Cancer Screening in the Southeast U.SMarvella E Ford, Louise Henderson, Alison Brenner, et al.
American Journal of Preventive Cardiology|September 2, 2025
Real-world prescribing in accordance to ACC/AHA guidelines for lipid-lowering therapy in high-risk primary and secondary prevention of ASCVD: Real-World Prescribing for Lipid-Lowering TherapyJonathan Arnold, Deeksha Acharya, Hetal Boricha, et al.
Pageof 110